{"Symbol": "AUPH", "AssetType": "Common Stock", "Name": "Aurinia Pharmaceuticals Inc", "Description": "Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "4464 Markham Street, Victoria, BC, Canada, V8Z 7X8", "FullTimeEmployees": "62", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "1737911808", "EBITDA": "-58641000", "PERatio": "None", "PEGRatio": "0", "BookValue": "2.121", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.697", "RevenuePerShareTTM": "0.003", "ProfitMargin": "0", "OperatingMarginTTM": "-305.8522", "ReturnOnAssetsTTM": "-0.2723", "ReturnOnEquityTTM": "-0.776", "RevenueTTM": "318000", "GrossProfitTTM": "-52548000", "DilutedEPSTTM": "-1.365", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "11.5", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "4443.1824", "PriceToBookRatio": "6.5281", "EVToRevenue": "4524.2634", "EVToEBITDA": "0", "Beta": "1.0299", "52WeekHigh": "21.93", "52WeekLow": "3.52", "50DayMovingAverage": "14.2986", "200DayMovingAverage": "15.5809", "SharesOutstanding": "126252000", "SharesFloat": "99231547", "SharesShort": "4834808", "SharesShortPriorMonth": "4305772", "ShortRatio": "1.88", "ShortPercentOutstanding": "0.03", "ShortPercentFloat": "0", "PercentInsiders": "17.108", "PercentInstitutions": "49.677", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:50", "LastSplitDate": "2013-10-23"}